InvestSMART

Immutep Limited (ASX: IMM) - Announcements

- Current share price for IMM : $0.023

ASX company news and announcements for Immutep Limited (IMM) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Immutep Limited (IMM) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Immutep Limited (IMM), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Immutep Limited (IMM)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$34 Recruitment of stage 1 of part B in TACTI-002 study complete 18 Aug 2020 8:18AM $0.190 $0.023 fallen by 87.89%
$34 Immutep Investor Update 17 Aug 2020 10:14AM $0.190 $0.023 fallen by 87.89%
$34 Immutep granted US patent for eftilagimod alpha 11 Aug 2020 6:33PM $0.185 $0.023 fallen by 87.57%
$34 Lapse of Unlisted Options 11 Aug 2020 6:07PM $0.185 $0.023 fallen by 87.57%
$34 Change in substantial holding 27 Jul 2020 8:12AM $0.210 $0.023 fallen by 89.05%
$34 Immutep Quarterly Activities Report & Appendix 4C 23 Jul 2020 8:21AM $0.200 $0.023 fallen by 88.50%
$34 Change in substantial holding 21 Jul 2020 8:26AM $0.180 $0.023 fallen by 87.22%
$34 US patent granted for IMP701 antibody 15 Jul 2020 8:14AM $0.145 $0.023 fallen by 84.14%
$34 Immutep Completes Recruitment for Part A of TACTI-002 trial 29 Jun 2020 8:21AM $0.155 $0.023 fallen by 85.16%
$34 Immutep receives A$1,437,826 R&D Tax Incentive 22 Jun 2020 8:17AM $0.155 $0.023 fallen by 85.16%
$34 Immutep announces improving data from TACTI-002 ph II trial 1 Jun 2020 8:19AM $0.185 $0.023 fallen by 87.57%
$34 Immutep Reports First Results from INSIGHT-004 Study 1 Jun 2020 8:18AM $0.185 $0.023 fallen by 87.57%
$34 Immutep receives $3.6M R&D French tax incentive 29 May 2020 8:55AM $0.185 $0.023 fallen by 87.57%
$34 Immutep webcast to present new data from 2020 ASCO meeting 27 May 2020 8:21AM $0.160 $0.023 fallen by 85.63%
$34 Becoming a substantial holder from AEF 7 May 2020 12:59PM $0.140 $0.023 fallen by 83.57%
$34 Immutep granted Japanese patent for eftilagimod alpha 7 May 2020 8:49AM $0.135 $0.023 fallen by 82.96%
$34 Change in substantial holding 7 May 2020 8:31AM $0.135 $0.023 fallen by 82.96%
$34 Cleansing Notice 5 May 2020 10:12AM $0.138 $0.023 fallen by 83.27%
$34 Appendix 2A 4 May 2020 11:13AM $0.135 $0.023 fallen by 82.96%
$34 Immutep presents at NWR Virtual Small Cap Health Conference 1 May 2020 8:20AM $0.175 $0.023 fallen by 86.86%
$34 INSIGHT-004 and TACTI-002 data to be presented at ASCO 30 Apr 2020 8:57AM $0.170 $0.023 fallen by 86.47%
$34 Proposed issue of Securities - IMM 29 Apr 2020 9:54AM $0.175 $0.023 fallen by 86.86%
$34 Proposed issue of Securities - IMM 29 Apr 2020 9:44AM $0.175 $0.023 fallen by 86.86%
$34 Immutep Investor Presentation 29 Apr 2020 9:28AM $0.175 $0.023 fallen by 86.86%
$34 Immutep completes A$12 million placement 29 Apr 2020 9:28AM $0.175 $0.023 fallen by 86.86%

576 - 600 of 791 results

Page 24 of 32

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.